Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network

Authors


  • Robert J. DiDomenico is a consultant for F. Hoffman LaRoche. J. Thomas Heywood has received speaking honoraria from Actelion, Medtronic, St Jude, and Thoratec; is a consultant for Actelion, Medtronic, and Thoratec; and has received research grants from Medtronic and Gambro and fellowship support from St. Jude. JoAnn Lindenfeld is a consultant for St Jude, Boston Scientific, and Abbott and has received a research grant from Zensun. J. Herbert Patterson has received speaking honoraria from Otsuka, is a consultant for Otsuka and Novartis, and has received research grants from Otsuka, Novartis, and Amgen. All of the other authors report no potential conflict of interest.

  • This paper represents the opinions of the Cardiology Practice and Research Network of the American College of Clinical Pharmacy (ACCP) and the Heart Failure Society of America (HFSA). It does not necessarily represent an official ACCP or HFSA commentary, guideline, or statement of policy or position.

  • This article was published in the Journal of Cardiac Failure, Vol 19, Issue 5, May 2013, Milfred-Laforest et al, “Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network” © 2013 Elsevier Inc.

For questions or comments, contact Sheryl L. Chow, Western University of Health Sciences, College of Pharmacy, 309 E. Second Street, Pomona, CA 91766; e-mail: schow@westernu.edu or Barry M. Massie, San Francisco VAMC, Cardiology Division (111C), 4150 Clement Street, San Francisco, CA 94143; e-mail: barry.massie@va.gov.

Abstract

Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a “perfect storm” of factors that predispose patients to medication errors. The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary HF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e.g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause readmissions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable. Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.

Ancillary